Abstract：Objective To explore the clinical application of soluble ST2 (sST2) in heart failure (HF) so as to provide a new basis for the clinical assessment of HF. Methods Fifty patients diagnosed with HF in the People’s Hospital of Hunan Province from January to December 2015 were selected as the experimental group, 34 cardiovascular disease patients without HF as the disease control group, and 44 health examinees as the healthy control group. Venous blood samples of the three groups were collected, and the levels of sST2 and NT-proBNP were detected. Clinical data of the experimental group were collected. The relationship between sST2 and HF was analyzed, and then the clinical value of sST2 and NT-proBNP in diagnosis of HF was compared. Results The average levels of sST2 in the experimental group, the disease control group and the healthy control group were(48.43±10.21)ng/ml, (24.69±9.35)ng/ml and(19.91±8.76) ng/ml respectively, and the differences were statistically significant (P<0.05). The average levels of sST2 in chronic and acute HF subgroups were(61.43±12.45)ng/ml and(35.41±12.23)ng/ml respectively, with a statistically significant difference (P<0.05). The average levels of sST2 in NYHA II, NYHA III and NYHA IV subgroups were (29.42±12.33)ng/ml,(36.19±10.42)ng/ml and(66.40±13.44)ng/ml respectively, with statistically significant differences (all P<0.05). No statistically significant differences were found in the average levels of sST2 among groups with different ages and pathogeny (P>0.05). The areas under the ROC curve of sST2 and NT-proBNP for distinguishing between HF and all control individuals were 0.753 (95%CI:0.630-0.877, P<0.01) and 0.848 (95%CI:0.763-0.934, P<0.01) respectively. Conclusions As a new serum marker, the level of sST2 is significantly increased in chronic HF, and correlated with the severity of HF. Combined detection of sST2 and NT-proBNP is conducive to correct diagnosis of HF.
李建英, 谭黎明. 可溶性ST2在心力衰竭评估中的应用价值[J]. 实用预防医学, 2017, 24(3): 361-364.
LI Jian-ying, TAN Li-ming. Application value of soluble ST2 assay in heart faliure. , 2017, 24(3): 361-364.
[1] Ahern RM, Lozano R, Naghavi M, et al. Improving the public health utility of global cardiovascular mortality data:the rise of ischemic heart disease[J]. Popul Health Metr, 2011, 9:8. [2] Friões F, Lourenço P, Laszczynska O, et al. Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction[J]. Clin Res Cardiol, 2015, 104(6):491-499. [3] 黄桂锋. 可溶性sT2和NT-proBNP在心力衰竭中的变化和临床意义[J]. 中国当代医药, 2015, 22(9):131-133. [4] 吕孝欣, 宋书凯, 蔡佩妍, 等. 慢性心力衰竭患者血清sST2水平与BNP及LVMI的相关性研究[J]. 临床合理用药, 2012, 5(3B):8-9. [5] 中华医学会心血管病学分会, 中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南[J]. 中华心血管病杂志, 2014, 42(2):98-122. [6] Sánchez-Más J, Lax A, Asensio-López Mdel C, et al. Modulation of IL-33/ST2 system in postinfarction heart failure:correlation with cardiac remodelling markers[J]. Eur J Clin Invest, 2014, 44(7):643-651. [7] De la Fuente M, MacDonald TT, Hermoso MA. The IL-33/ST2 axis: role in health and disease[J]. Cytokine Growth Factor Rev, 2015, 101(15):65-69. [8] 王霞. 可溶性sT2在心力衰竭中的临床应用前景[J]. 国际检验医学杂志, 2015, 36(3):387-389. [9] AshleyM, Miller. IL-33 reduces the development of atherosclerosis[J]. J ExpMed, 2008, 205:339-346. [10] Januzzi JL Jr, Peacock WF, Maisel AS, et al. Measurement of the interleukin family member ST2 in patients with acute dyspnea:results from the PRIDE (pro-brain natriuretic peptide investigation of dyspnea in the emergency department) study[J]. J Am Coll Cardiol, 2007, 50:607-613. [11] Januzzi JL Jr, Sakhuja R, O'donoghue M, et al. Utility of amino-terminal pro-brain natriuretic peptide testing for prediction of 1-year mortality in patients with dyspnea treated in the emergency department[J]. Arch Intern Med, 2006, 166(3):315-320. [12] Bayes-Genis A, Zamora E, de Antonio M, et al. Soluble ST2 serum concentration and renal function in heart failure[J]. J Card Fail, 2013, 19(11):768-775. [13] Stienen S, Salah K, Eurlings LW, et al. Targeting N-terminal pro-brain natriuretic peptide in older versus younger acute decompensated heart failure patients[J]. JACC Heart Fail, 2016, S2213-1779(16):30225-30226. [14] Januzzi JL, Mebazaa A, Di Somma S, et al. ST2 and prognosis in acutely decompensated heart failure:the International ST2 Consensus Panel[J]. Am J Cardiol, 2015, 115(7 Suppl):26B-31B. [15] Felker GM, Fiuzat M, Thompson V, et al. Soluble ST2 in ambulatory patients with heart failure: association with functional capacity and long-term outcomes[J]. Circ Heart Fail, 2013, 6(6):1172-1179. [16] Lancellotti P, Dulgheru R, Magne J, et al. Elevated plasma soluble ST2 is associated with heart failure symptoms and outcome in aortic stenosis[J]. PLoS One, 2015, 10(9):e0138940. [17] Lassus J, Gayat E, Mueller C, et al. Incremental value of biomarkers to clinical variables for mortality prediction in acutely decompensated heartfailure:the Multinational Observational Cohort on Acute Heart Failure (MOCA) study[J]. Int J Cardiol, 2013, 168(3):2186-2194. [18] Rehman SU, Mueller T, Januzzi JL Jr. Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure[J]. J Am Coll Cardiol, 2008, 52(18):1458-1465.
2017, Vol. 24 
